NYSE:ABTAbbott Laboratories Stock Price, Forecast & News

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ABT shares have increased by 4.9% and is now trading at $81.93. View which stocks have been mosted impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 1 sell rating, 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Abbott Laboratories.

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, April 16th 2020. View our earnings forecast for Abbott Laboratories.

Abbott Laboratories will be holding an earnings conference call on Thursday, April 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Abbott Laboratories (NYSE:ABT) released its quarterly earnings data on Wednesday, January, 22nd. The healthcare product maker reported $0.95 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.95. The healthcare product maker earned $8.31 billion during the quarter, compared to analyst estimates of $8.26 billion. Abbott Laboratories had a return on equity of 18.39% and a net margin of 11.56%. Abbott Laboratories's revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.81 EPS. View Abbott Laboratories' earnings history.

Abbott Laboratories declared a quarterly dividend on Friday, February 21st. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.36 per share on Friday, May 15th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.76%. The ex-dividend date of this dividend is Tuesday, April 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.08. View Abbott Laboratories' dividend history.

Abbott Laboratories updated its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share (EPS) guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.60.

18 Wall Street analysts have issued twelve-month target prices for Abbott Laboratories' stock. Their forecasts range from $81.00 to $105.00. On average, they expect Abbott Laboratories' share price to reach $94.43 in the next year. This suggests a possible upside of 15.3% from the stock's current price. View analysts' price targets for Abbott Laboratories.

Headlines about ABT stock have trended very negative on Wednesday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Abbott Laboratories earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned press coverage about the healthcare product maker a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAbbott Laboratories.

Abbott Laboratories saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 23,053,500 shares, an increase of 21.5% from the February 27th total of 18,970,000 shares. Based on an average trading volume of 5,550,000 shares, the days-to-cover ratio is presently 4.2 days. Approximately 1.3% of the shares of the company are sold short. View Abbott Laboratories' Current Options Chain.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD), Masimo (MASI) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Johnson & Johnson (JNJ), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Home Depot (HD), Pfizer (PFE), Verizon Communications (VZ) and Intel (INTC).

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include Park National Corp OH (0.03%), State of Alaska Department of Revenue (0.02%), Centre Asset Management LLC (0.01%), First Financial Bank Trust Division (0.01%), Woodstock Corp (0.01%) and Callahan Advisors LLC (0.01%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Philip P Boudreau, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View institutional ownership trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Centre Asset Management LLC, Park National Corp OH, Global Trust Asset Management LLC, Birch Capital Management LLC, Callahan Advisors LLC, IMS Capital Management, Enterprise Bank & Trust Co, and CHICAGO TRUST Co NA. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Philip P Boudreau, Randel William Woodgrift, Sally E Blount, and Stephen R Fussell. View insider buying and selling activity for Abbott Laboratories.

ABT stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, IBM Retirement Fund, Cullinan Associates Inc., Gradient Investments LLC, Fulton Bank N.A., First Financial Bank Trust Division, American National Bank, and Mitchell Sinkler & Starr PA. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift. View insider buying and selling activity for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $81.93.

Abbott Laboratories has a market capitalization of $144.48 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe. View additional information about Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.